Drugs / Eloralintide
Eloralintide
Trials 20
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 110 trials | ||||||
| Phase 1 | NCT07808060 | Sep 2026 → Jun 2027 expected | obesity disorder | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 1 | NCT07701083 | Jul → Oct 2026 expected | — | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 1 | NCT07665879 | Jun 2026 → Aug 2027 expected | obesity disorder | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 1 | NCT07426380 | Feb → Oct 2026 expected | chronic renal failure syndrome, end stage renal failure, impaired renal function disease | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 1 | NCT07401862 | Feb 2026 → Mar 2027 expected | liver disorder | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 1 | NCT06916091 | Apr → Sep 2025 | obesity disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT06916065 | Apr 2025 → Jan 2026 | obesity disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT06297616 | Apr 2024 → Nov 2025 | obesity disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT06345066 | Apr 2024 → Sep 2025 | obesity disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT05295940 | Mar 2022 → Jan 2024 | obesity disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT07589608 | May 2026 → Sep 2027 expected | obesity disorder | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 2 | NCT07215559 | Oct 2025 → Mar 2027 expected | obesity disorder, type 2 diabetes mellitus | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06603571 | Sep 2024 → Jul 2026 | obesity disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT06230523 | Feb 2024 → May 2025 | obesity disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT06143956 | Nov 2023 → Sep 2027 expected | obesity disorder | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 35 trials | ||||||
| Phase 3 | NCT07392190 | Feb 2026 → Jun 2028 expected | obesity disorder | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 3 | NCT07369011 | Feb 2026 → Mar 2028 expected | obesity disorder, obstructive sleep apnea syndrome | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 3 | NCT07353931 | Feb 2026 → Mar 2028 expected | obesity disorder, osteoarthritis | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 3 | NCT07321886 | Feb 2026 → Mar 2028 expected | obesity disorder | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 3 | NCT07282600 | Dec 2025 → Jan 2028 expected | obesity disorder | Eli Lilly and Company | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2026-09-30 | Eli Lilly and Company | Results Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes lilly.com ↗
At 48 weeks, all combinations of EloraTZP met the primary and secondary endpoints, delivering substantial weight loss and A1C reduction. |
| 2026-09-15 | Eli Lilly and Company | Results Lilly to present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026, as it strives to change the course of cardiometabolic health lilly.com ↗
EloraTZP Phase 1 Results: Adding eloralintide 3 mg to tirzepatide 5 mg led to 17% weight loss over 16 weeks versus 10% with tirzepatide 5 mg alone in adults with obesity or overweight. |
| 2025-11-06 | Eli Lilly and Company | Results Lilly's selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweight lilly.com ↗
At 48 weeks, all treatment arms of eloralintide met the primary endpoint, demonstrating superior mean weight reductions from 9.5% to 20.1% compared to 0.4% with placebo using the efficacy estimand. |
| 2025-05-29 | Eli Lilly and Company | Results Lilly announces details of presentations at American Diabetes Association's (ADA) 85th Scientific Sessions lilly.com ↗
Eloralintide (LY3841136), a Selective Amylin Mimetic, Lowered Body Weight with Improved Quality of Weight Loss and GI Tolerability in Rats Compared with Cagrilintide |
All press releases naming this drug 4 releases
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 22 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Eloralintide | “Eloralintide (LY3841136), a novel amylin analog, was evaluated in translational studies to characterize its therapeutic potential for treating obesity.” PMID 41109426 ↗ Oct 2025 |
| Known as | AMY-1176 | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068462 ↗ |
| Known as | Eloralintida | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068462 ↗ |
| Known as | LY3841136 | “A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity” NCT06916065 ↗ |
| Action | Activate | “Eloralintide preferentially activated human AMY1R” PMID 41109426 ↗ Oct 2025 |
| Modality | Peptide | “Eloralintide (LY3841136), a novel amylin analog, was evaluated in translational studies to characterize its therapeutic potential for treating obesity.” PMID 41109426 ↗ Oct 2025 |
| Modality | Protein / enzyme biologic | — CHEMBL6068462 ↗ |
| Route | Subcutaneous | “Single ascending doses of LY3841136 administered subcutaneously (SC).” NCT05295940 ↗ |